Premium
Immunosuppression in pediatric liver transplantation: Are little people different?
Author(s) -
Dhawan Anil
Publication year - 2011
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.22422
Subject(s) - medicine , immunosuppression , sirolimus , hepatocellular carcinoma , liver transplantation , intensive care medicine , clinical trial , transplantation , mycophenolic acid , viral hepatitis , pediatrics
Key Points 1. Children differ from adults in the pharmacokinetics and dynamics of most immunosuppressive agents. 2. A lack of clinical trials continues to be an issue for newer agents. 3. On the basis of clinical case series, mycophenolate mofetil and sirolimus are increasingly being used as renal‐sparing agents. 4. In comparison with adults, the recurrence of both viral hepatitis and hepatocellular carcinoma is less of an issue in children. 5. Particular attention should be paid to complete age‐appropriate immunization to avoid vaccine‐preventable diseases. 6. Paying special attention to adherence and the transition to adult services is essential for minimizing graft loss. Liver Transpl, 2011. © 2011 AASLD.